Amyloidosis medical therapy: Difference between revisions
Shyam Patel (talk | contribs) No edit summary |
Shyam Patel (talk | contribs) |
||
Line 13: | Line 13: | ||
**[[Heart failure]] is treated using [[diuretics]]. | **[[Heart failure]] is treated using [[diuretics]]. | ||
**Gastrointestinal and nerve involvement are treated symptomatically. | **Gastrointestinal and nerve involvement are treated symptomatically. | ||
The most commonly used regimen is CyBorD, which consists of cyclophosphamide, bortezomib, and dexamethasone. | The most commonly used regimen for AL amyloidosis is CyBorD, which consists of cyclophosphamide, bortezomib, and dexamethasone.<ref name="pmid29854961">{{cite journal| author=Milani P, Merlini G, Palladini G| title=Novel Therapies in Light Chain Amyloidosis. | journal=Kidney Int Rep | year= 2018 | volume= 3 | issue= 3 | pages= 530-541 | pmid=29854961 | doi=10.1016/j.ekir.2017.11.017 | pmc=5976806 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29854961 }} </ref> | ||
{| | {| | ||
| valign="top" | | | valign="top" | | ||
Line 66: | Line 66: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
Myelosuppression, nausea, vomiting, hemorrhagic cystitis, secondary malignancies | Myelosuppression, nausea, vomiting, hemorrhagic cystitis, secondary malignancies | ||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | |||
Patisiran | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*RNA interference therapy | |||
*Inhibits hepatic synthesis of transthyretin | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*0.3mg/kg every weekly | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
Dyspepsia, dyspnea, erythema, bronchitis, blurry vision | |||
|- | |- | ||
|} | |} |
Revision as of 19:42, 2 January 2019
Amyloidosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Amyloidosis medical therapy On the Web |
American Roentgen Ray Society Images of Amyloidosis medical therapy |
Risk calculators and risk factors for Amyloidosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]; Associate Editor(s)-in-Chief:
Overview
There are few available treatments for primary amyloidosis. Since the disease is typically discovered at an advanced stage, the initial treatment is aimed at preventing further organ damage and correcting the effects of organ failure.
Medical Therapy
Some patients with primary amyloidosis respond to chemotherapy focused on the abnormal plasma cells. A stem cell transplant may be done, as in multiple myeloma.
- The initial target in the treatment of this disorder is to correct the organ failure, as the disease is discovered at an advanced stage.
- Nephrotic syndrome is treated using supportive therapy and diuretics.
- Renal failure is treated with dialysis.
- Heart failure is treated using diuretics.
- Gastrointestinal and nerve involvement are treated symptomatically.
The most commonly used regimen for AL amyloidosis is CyBorD, which consists of cyclophosphamide, bortezomib, and dexamethasone.[1]
Therapy | Mechanism of Action | Dosing | Adverse Effects |
---|---|---|---|
Bortezomib |
|
|
Peripheral neuropathy, VZV reactivation, hepatic impairment, asthenia, diarrhea, nausea, constipation, arthralgia, edema, dizziness |
Dexamethasone |
|
|
Infections, immunosuppression, bone loss, cataract formation, glaucoma, muscular atrophy |
Melphalan |
|
|
Myelosuppression, nausea, vomiting, pulmonary fibrosis, stomatitis |
Cyclophosphamide |
|
|
Myelosuppression, nausea, vomiting, hemorrhagic cystitis, secondary malignancies |
Patisiran |
|
|
Dyspepsia, dyspnea, erythema, bronchitis, blurry vision |
Treatment options with limited success include melphalan, prednisone, and colchicine.
In secondary amyloidosis, aggressively treating the disease that is causing the excess amyloid protein can improve symptoms and/or slow the disease from getting worse. Complications such as heart failure, renal failure, and other problems can sometimes be treated, when needed.
References
- ↑ Milani P, Merlini G, Palladini G (2018). "Novel Therapies in Light Chain Amyloidosis". Kidney Int Rep. 3 (3): 530–541. doi:10.1016/j.ekir.2017.11.017. PMC 5976806. PMID 29854961.